TDO2 and neoplasm: IDO1/TDO2 inhibitors suppress tumor formation in animal models and are currently being evaluated in clinical trials against a wide range of cancers, including melanoma, glioblastoma, non–small cell lung cancer, and pancreatic and breast cancers [67,71,75].